Loading company…
TolerogenixX GmbH develops personalized cell therapies designed to induce immune tolerance in transplant patients.
Founded in 2016 and based in Heidelberg, Germany, TolerogenixX GmbH develops personalized cellular therapies aimed at immune tolerance, mainly for organ transplant recipients and patients with autoimmune diseases. Its lead therapy, MIC-Lx, modifies immune cells from living donors. On July 4, 2023 the company raised EUR 7 million led by DB Speciality Invest GmbH & Co. KG, and CEO Matthias Schaier leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in